Abstract Library

#2884 An Infectious Diseases Specialist NET Patient Looks at Management of NETs

Introduction: Medical specialties may develop practices minimally influenced by other specialties.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Schmid G,

Keywords: neuroendocrine, everolimus, somatostatin analogue, drug levels,

#1596 Triple Tracer Imaging Approach for the Non-Invasive Assessment of Chemokine Receptor 4 Expression in Gastroenteropancreatic Neuroendocrine Tumors

Introduction: The theranostic twins [68Ga]Pentixafor and [177Lu]Pentixather for chemokine-directed endoradiotherapy (ERT) were recently developed.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Werner R

Authors: Werner R, Weich A, Higuchi T, Schmid J, Schirbel A,

Keywords: Neuroendocrine tumor, [68Ga]Pentixafor, CXCR4, PRRT, PET/CT,

#1588 Response Prediction for Vandetanib Treatment in Recurrent Medullary Thyroid Carcinoma using F18-FDG PET

Introduction: Given its neuroendocrine origin, the prognosis of medullary thyroid carcinoma (MTC) remained poor in common chemotherapeutic approaches. However, the encouraging results of tyrosine kinase inhibitors (TKI) such as vandetanib emphasize the high demand for selecting appropriate candidates.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Werner R

Authors: Werner R, Schmid J, Higuchi T, Buck A, Aulmann C,

Keywords: FDG, MTC,

#1162 Comparative Marker Assessment in Small Cell Lung Cancer with Good and Poor Prognosis

Introduction: Small cell lung cancers (SCLC) are highly aggressive and poorly differentiated neuroendocrine neoplasms which comprise ̴̴̴15 % of all lung malignancies.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Schmidt L, Specht E, Reimann C, Kaemmerer D, Wirtz R,

Keywords: SCLC, SSTR, CXCR4, proliferation,

#446 Comparative Expression Analysis of Somatostatin Receptor Subtypes in Human Neuroendocrine Tumors Using Two Sets of New Monoclonal Antibodies

Introduction: Expression of somatostatin receptor subtypes (sstr) is required for the successful use of somatostatin analogues (SSA) in the treatment of neuroendocrine tumors (NET). Reliable detection of sstr could improve the selection of SSA treatment. Rabbit and mouse monoclonal antibodies (mAbs) were recently developed independently in Jena and Basel.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Lambertini C, Nuciforo P, Schulz S, Schmid H,

Keywords: sstr, NET, sstr-specific mAb,